Utilization of the serosal scarification model of postoperative intestinal adhesion formation to investigate potential adhesion-preventing substances in the rabbit.
A rabbit serosal scarification model was utilized to compare the ability of four drugs, previously administered peri-operatively to horses undergoing exploratory celiotomy, to prevent the development of postoperative intestinal adhesions. The substances compared were 32% Dextran 70 (7 mL/kg), 1% sodium carboxymethylcellulose (7 mL/kg), trimethoprim-sulfadiazine (30 mg/kg), and flunixin meglumine (1 mg/kg). The first two were administered intra-abdominally following surgery, while the latter two were administered systemically in the peri-operative period. Fibrous adhesions were evident in all animals in the untreated serosal scarification group. No significant difference in the number of animals with adhesions was found between the untreated control group and any treatment group, nor among the treatment groups. Microscopic examination of adhesions collected at postmortem examination revealed fibers consistent with cotton, surrounded by a giant-cell reaction and ongoing acute inflammation. The source of the fibers was likely the cotton laparotomy sponges used to scarify the intestinal surface, since the pattern in the granuloma and sponge fibers appeared similar under polarized light. Though consistent intestinal adhesion formation was produced in the rabbit, the presence of foreign body granulomas may prevent consideration of this model for future research. The drugs tested were ineffective in preventing the formation of postoperative small intestinal adhesions in this model.
Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Ontario.
E R
ER
Singer
M A
MA
Livesey
I K
IK
Barker
M B
MB
Hurtig
P D
PD
Conlon
D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use*; D002266:Carboxymethylcellulose Sodium / Q000627:therapeutic use*; D002921:Cicatrix / Q000473:pathology / Q000662:veterinary*; D003002:Clonixin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003911:Dextrans / Q000627:therapeutic use*; D004195:Disease Models, Animal; D007579:Jejunal Diseases / Q000473:pathology / Q000517:prevention & control / Q000662:veterinary; D007583:Jejunum / Q000187:drug effects / Q000473:pathology; D011183:Postoperative Complications / Q000188:drug therapy / Q000517:prevention & control / Q000662:veterinary*; D011817:Rabbits / Q000601:surgery*; D011897:Random Allocation; D013411:Sulfadiazine / Q000627:therapeutic use*; D000267:Tissue Adhesions / Q000209:etiology / Q000517:prevention & control / Q000662:veterinary*; D014295:Trimethoprim / Q000627:therapeutic use*
D000890:Anti-Infective Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000925:Anticoagulants; D003911:Dextrans; D013411:Sulfadiazine; C014558:flunixin meglumine; D014295:Trimethoprim; D002266:Carboxymethylcellulose Sodium; D003002:Clonixin